Journal
PEDIATRIC BLOOD & CANCER
Volume 61, Issue 4, Pages 749-752Publisher
WILEY-BLACKWELL
DOI: 10.1002/pbc.24778
Keywords
cancer biology; clinical trials; osteosarcoma
Categories
Funding
- Chair's Grant [U10 CA98543]
- NCI, NIH, Bethesda, MD, USA [U24 CA114766]
- QuadW Foundaton
- AFLAC
- Children's Cancer Foundation (Baltimore MD)
- Go4theGoal
- Dani's Foundation
- Alex's Lemonade Stand Foundation
- Liddy Shriver Sarcoma Initiative, Burroughs Wellcome Clinical Scientist Award in Translational Research
- NIH [R01CA88004, R01CA133662, R01CA138212, RC4CA156509]
Ask authors/readers for more resources
To investigate the role of insulin-like growth factor-1 (IGF-1), in localized osteosarcoma, serum levels of IGF-1, IGFBP-2, and IGFBP-3 were measured in 224 similarly treated, newly diagnosed patients. We demonstrated that younger patients had lower concentrations of IGF-1 and IGFBP-3 compared to older (P<0.001) along with lower IGFBP-3:IGF-1 and IGFBP-2:IGF-1 ratios (P<0.001). IGFBP-2 did not correlate with age (P=0.16), yet IGFBP-2:IGF-1 ratios were higher in the younger population (P<0.001). These findings show that older patients have higher concentrations of free IGF-1. None of IGF-1, IGFBP-2, nor IGFBP-3 concentrations were associated with event-free nor overall survival. Pediatr Blood Cancer 2014;61:749-752. (c) 2013 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
